Double-Blind Placebo-Controlled Trial of Quetiapine in Anorexia Nervosa.
About this resource
Objective: Our objective is to determine whether quetiapine was superior to placebo in increasing weight or reducing core symptoms of anorexia nervosa as assessed by the Yale–Brown–Cornell Eating Disorder Scale and the Eating Disorder Inventory-2. Method: Participants were randomised to 8 weeks of quetiapine or placebo. Results: There are 21 participants who signed informed consent, 15 were randomised, 14 returned for at least one visit after receiving drug and 10 completed the study. There were no differences between drug and placebo in questionnaire scores, weight or measures of anxiety or depression. Discussion: There was no difference between quetiapine and placebo on weight gain or core symptoms. Small effect sizes suggest that a higher number of participants would not increase significant differences between groups. Copyright © 2012 John Wiley & Sons, Ltd and Eating Disorders Association.
ED management of patients with eating disorders
BACKGROUND: Eating disorders are one of the "great masqueraders" of the twenty-first century.Read more
DSM-IV-defined anorexia nervosa versus subthreshold anorexia nervosa (EDNOS-AN)
OBJECTIVES: Eating disorder not otherwise specified (EDNOS) is the most prevalent eating disorder, yet its heterogeneity begs less reliance on this broad diagnostic category.Read more
The effects of intranasal oxytocin on smoothie intake, cortisol and attentional bias in anorexia nervosa.
BACKGROUND: Anorexia nervosa (AN) is characterised by severe malnutrition as well as intense fear and anxiety around food and eating with associated anomalies in information processing.Read more